The product range is unique and it is entirely focused on companion animals and horse. The majority of our key products are novel or have clear marketing advantages over competitor products. Most of our branded range have market leading positions in the majority of territories in which we operate.

Dermatology

Canaural^® was first licensed in 1975 and is still the leading first line treatment for otitis externa in cats and dogs in several EU territories. Canaural, which is now registered in 27 countries, can also be used in conjunction with our leading ear cleaning product CleanAural^®.

Fuciderm^®, licensed in 1995, is the only licensed product for the treatment of surface pyoderma in dogs, such as acute moist dermatitis and intertrigo. It is a key product within our dermatology range, selling into 23 countries.

Malaseb^® was first licensed in 1996 and is still the market leading medicated shampoo for cats and dogs. It is used to treat skin disease caused by Malassezia and Staphylococcal infections.

Animax^®, licensed for the treatment of skin conditions in dogs and cats, is only approved in the US. The marketing rights for this product were acquired in May 2007.

Endocrinology

Endocrine disorders are a key focus for the business with a number of licensed products treating a range of chronic diseases. The two leading brands are Vetoryl^® and Felimazole^®.

Vetoryl is a novel product for the treatment of Cushing’s Disease (excess cortisol or hyperadrenocorticism) in dogs. It is marketed internationally and is the only recognised licensed efficacious veterinary product for the treatment of Cushing’s Disease around the world.

Felimazole was the first veterinary licensed product for the treatment of feline hyperthyroidism.  Originally licensed in the UK in 2002, Felimazole was licensed in the EU in 2005, the US in 2009 and has been submitted for approval in new markets.

Equine Medicine

We have a wide range of 14 licensed products supporting the equine veterinarian. The lead product with the highest sales is Equipalazone^® which is licensed in five major EU countries.

Equipalazone was first licensed in a sachet presentation in 1972 and subsequently in a paste and injection. It is still the leading non-steroidal anti-inflammatory drug (NSAID) for the treatment of musculoskeletal disorders, such as lameness due to acute and chronic laminitis in the horse. 

Equidone^® gel was approved in 2010 for the treatment of fescue toxicity in horses. This niche product is targeted specifically at the US market.

Opthalmology

Opthalmology is a highly specialised area of veterinary medicine where we have a number of leading products including licensed pharmaceuticals, unlicensed care products and instruments.

Fucithalmic^® Vet, licensed in 1993, is the only licensed product available for the treatment of conjunctivitis associated with staphylococcal infections. It is highly effective because its unique sustained release formulation that ensures prolonged retention within the eye. It is currently licensed in 21 countries worldwide.

We also market a range of ophthalmic and otic products in the US, the long-term marketing rights of which were acquired in May 2007. There are six products in the range, most of which are the only veterinary licensed products in the American market.

Critical Care

Dechra has a wide range of products that support emergency medicine including licensed pharmaceuticals, wound treatments, consumables and instruments all predominantly sold in the UK. The leading range of products is the Vetivex^®brand.

The Vetivex range of infusion fluids are licensed for the treatment of dehydration. They are widely used to meet normal fluid and electrolyte requirements when fluids cannot be given orally, such as during surgery. 

Libromide^®, acquired as part of the Genitrix^® acquisition, was approved in 2010. It is the only licensed product of its type which is used in combination with other pharmaceuticals for the management of epilepsy in dogs.

Generics

Several generic products are registered within the United Kingdom; this basket of products is marketed under the Dechra Veterinary Essentials™ brand. A number of products are also registered in Europe and we are in the process of in-licensing and registering additional products to extend our generic range within this territory.

Pet Diets

Dechra has two main cat and dog diet product ranges, both branded SPECIFIC^TM, which are sold exclusively through veterinary practices. Therapeutic diets, which represent 70% of diet sales, provide optimum levels of nutrition in areas such as diabetes, arthritis and urinary, kidney, liver and heart problems. Life stage diets, which represent 30% of diet sales, provide premium quality daily nutrition for healthy dogs and cats.

Care

The Care range comprises unlicensed products which complement our pharmaceutical range. They are available over the counter within veterinary practices. The three key products are CleanAural, a non irritant cleaner suitable for frequent use in ears producing excess wax; Neutrale™, a range of specialist shampoos for skin conditions in dogs and Lubrithal^®, an eye lubricant for cats and dogs.

Marketing Agreements
A number of products are also sold through our global subsidiaries under marketing agreements with:

- Eurovet to market Domidine^®, Sedator^® and Atipam^® in the UK and Ireland;
- Orthogen to market Irap^® in the USA;
- Peptech Animal Health Pty Limited (“Peptech”) to market Ovuplant^® in the USA, Canada and EU; and
- Krka to market Rycarfa^® in the EU